Constellation Pharmaceuticals
Biopharmaceutical company focused on developing novel therapeutics that target disease-related gene expression through epigenetic modulation. Acquired by MorphoSys in 2021.
Location
Cambridge, Massachusetts, USA
Founded
2008
Categories
biotech, pharmaceuticals, epigenetics, oncology, hematology
Notes
Constellation Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target gene expression through epigenetic modulation. The company specialized in developing treatments for hematological malignancies and solid tumors.
In July 2021, MorphoSys AG acquired Constellation Pharmaceuticals for approximately $1.7 billion. The acquisition brought pelabresib, a BET inhibitor being developed for myelofibrosis, into MorphoSys's pipeline.
Team (Pre-Acquisition)
- Jigar Raythatha - Former President & Chief Executive Officer
- LinkedIn: linkedin.com/in/jigarraythatha
- Patrick Trojer, Ph.D. - Former Chief Scientific Officer
Additional Research Findings
- Acquired by MorphoSys AG in July 2021 for $1.7 billion
- Former NASDAQ: CNST (now delisted)
- Epigenetic drug discovery platform
- Lead program: pelabresib (BET inhibitor) for myelofibrosis
- Focus on hematological malignancies
- Backed by Bain Capital Life Sciences
- Cambridge, Massachusetts headquarters
- Part of MorphoSys portfolio post-acquisition